Seelos Therapeutics Begins Dosing in Phase 1 PK/KD Study

Seelos Therapeutics (NASDAQ:SEEL) has announced it has dosed the first patients in its Phase I Pharmacokinetic (PK) and Pharmacodynamic (PD) profile study, SLS-002-102.

As quoted in the press release:

SLS-002-102 is a two-part, randomized, double-blind, placebo-controlled, parallel and crossover study of intranasal and intravenous ketamine which plans to enroll 62 healthy volunteers.

• 48 subjects in Part A (parallel) will be randomized into four arms to receive either 30mg, 75mg, 90mg of SLS-002 or placebo over 13 days.
• 14 subjects in Part B (crossover) will be randomized into three arms; 60mg of IV ketamine followed by 60mg SLS-002, 60mg SLS-002 followed by 60mg of IV ketamine, or placebo over 25 days.

“This study should help clarify SLS-002’s safety and tolerability across multiple intranasal doses, as well help to identify and understand any pharmacokinetic or pharmacodynamic differences compared with IV ketamine. This information will assist us in confirming the dosing strategy for the planned proof of concept study in patients with MDD suffering from ASIB,” said Raj Mehra, Ph.D., Chairman and CEO of Seelos Therapeutics.

Preliminary data from this study is expected in the first quarter of 2020.

Click here to read the full press release.